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A B S T R A C T
Background
Exposure to alcohol during brain development may cause a neurological syndrome called
fetal alcohol syndrome (FAS). Ethanol induces apoptotic neuronal death at specific
developmental stages, particularly during the brain-growth spurt, which occurs from the
beginning of third trimester of gestation and continues for several years after birth in humans,
whilst occuring in the first two postnatal weeks in mice. Administration of a single dose of
ethanol in 7-d postnatal (P7) mice triggers activation of caspase-3 and widespread apoptotic
neuronal death in the forebrain, providing a possible explanation for the microencephaly
observed in human FAS. The present study was aimed at determining whether nicotinamide
may prevent ethanol-induced neurodegeneration.
Methods and Findings
P7 mice were treated with a single dose of ethanol (5g/kg), and nicotinamide was
administered from 0 h to 8 h after ethanol exposure. The effects of nicotinamide on ethanol-
induced activation of caspase-3 and release of cytochrome-c from the mitochondria were
analyzed by Western blot (n ¼ 4–7/group). Density of Fluoro-Jade B–positive cells and NeuN-
positive cells was determined in the cingulated cortex, CA1 region of the hippocampus, and
lateral dorsal nucleus of the thalamus (n ¼ 5–6/group). Open field, plus maze, and fear
conditioning tests were used to study the behavior in adult mice (n ¼ 31–34/group).
Nicotinamide reduced the activation of caspase-3 (85.14 6 4.1%) and the release of
cytochrome-c (80.78 6 4.39%) in postnatal mouse forebrain, too. Nicotinamide prevented
also the ethanol-induced increase of apoptosis. We demonstrated that ethanol-exposed mice
showed impaired performance in the fear conditioning test and increased activity in the open
field and in the plus maze. Administration of nicotinamide prevented all these behavioral
abnormalities in ethanol-exposed mice.
Conclusions
Our findings indicate that nicotinamide can prevent some of the deleterious effects of
ethanol on the developing mouse brain when given shortly after ethanol exposure. These
results suggest that nicotinamide, which has been used in humans for the treatment of
diabetes and bullous pemphigoid, may hold promise as a preventive therapy of FAS.
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Introduction
Ethanol exposure during brain development can provoke
neurodevelopmental defects referred to as fetal alcohol
effects (FAE) or fetal alcohol syndrome (FAS), depending on
their severity [1], with an array of neurological disorders
including hyperactivity, learning and memory deficits, mental
retardation, psychosis, depression, and schizophrenia [2,3]. A
number of mechanisms have been proposed to contribute to
ethanol neurotoxicity: oxidative stress, induction of apopto-
sis, excitotoxicity, disruption of cell–cell interaction, and
interference with the activity of growth factors [4]. Several
lines of evidence point out that consuming many drinks per
occasion (i.e., binge drinking) is particularly harmful to the
developing brain [5]. Ethanol may damage the developing
brain by affecting neurogenesis, migration, or survival of cells
[6,7]. Neurons are more susceptible to ethanol-induced
apoptotic cell death during synaptogenesis, also known as
the brain growth spurt [8,9], which in humans takes place
during the third trimester of pregnancy, continuing for
several years after birth [10]. Epidemiological studies indicate
that FAS is the major non-genetic cause of mental retarda-
tion in the Western world [11]. Despite attempts to increase
awareness of FAS, consumption of alcohol during pregnancy,
especially binge drinking, has increased in recent years, and
currently there are no effective treatments to prevent or
revert FAS after ethanol exposure.
Studies of alcohol exposure in developmental animal
models are excellent tools to identify possible mechanisms
and interventions that may prevent or attenuate ethanol’s
effect on the developing brain. A single heavy episode of
ethanol exposure (binge-like drinking) in 7-d postnatal (P7)
mice, a period of brain development that is comparable to
the human third trimester, triggers widespread neurodegen-
eration, resulting in the loss of millions of neurons [12].
Transplacental ethanol exposure in guinea pigs during
synaptogenesis (a prenatal phenomenon in this species)
promotes a similarly intense apoptotic response in the fetal
brain [13]. Neurodegeneration could provide a likely explan-
ation for the reduced brain mass and neurobehavioral
disturbances observed in human FAS. The cell death
produced by ethanol in mice appears to be associated with
activation of caspase-3, an executioner protease that is
activated during apoptotic cell death [14,15].
Nicotinamide, an amide of vitamin B3, is the precursor for
the coenzyme b-nicotinamide adenine dinucleotide (NADþ)
and is considered to be necessary for cellular function and
metabolism. Recently, interest in nicotinamide has shifted
from its role as a nutrient to that as a novel neuroprotective
agent [16]. Treatment with nicotinamide enhances neuronal
survival during a variety of insults such as free radical
exposure and oxidative stress [17,18], and in animals
improves neurological outcome and reduces infarct volume
in transient and permanent focal ischemia in vivo [19–21].
The mechanism of nicotinamide-mediated neuroprotection
in vitro may be in part due to inhibition of caspase-3 and
release of cytochrome-c from mitochondria during oxygen–
glucose deprivation [22,23].
Based on these observations, we investigate whether
nicotinamide is able to prevent the neurotoxic effects of
ethanol exposure in the postnatal brain of mice. Further-
more, we analyze whether inhibition of ethanol-induced
apoptotic neuronal death is sufficient to prevent behavioral
impairment in adult mice.
Methods
Animals
P7 CD1 mice were injected subcutaneously with 20%
ethanol in saline solution delivering 5g/kg body weight, and
sacrificed at several time points. Nicotinamide and 1-methyl-
nicotinamide (Sigma, St. Louis, Missouri, United States) were
dissolved in saline solution (50mg/ml) and were administered
subcutaneously at different doses (0.25, 0.5, and 1mg/g) and
time points (0, 2, 4, or 8 h) after ethanol injection. Saline
injections of equal volume were used as controls. In each
litter, animals were equally distributed into the different
treatment groups (see Table S1). Animal care was provided
according to the guidelines of Weill Medical College of
Cornell University.
Western Blot Analysis
Animals were killed at 2, 4, 8, 12, and 24 h after ethanol
administration (see Table S1). Brains were rapidly dissected
out, and cerebellum, brain stem, and olfactory bulb were
carefully removed and tissue was frozen in dry ice. For each
treatment group, four to seven pups from 14 different litters
were analyzed.
Caspase-3 Western Blot
Caspase-3 analysis was done as previously described with
some modifications [15]. Forebrains were divided in half and
lysed in boiling SDS buffer (250 mM tris-HCl [pH 6.8], 2.5%
SDS) followed by brief sonication and further centrifuged at
14,000 g for 20 min. Supernatant was collected and stored at
#80 8C until further analysis.
Cytochrome-C Western Blot
In order to analyze the release of cytochrome-c from the
mitochondria into the cytoplasm, fresh tissue was prepared as
previously described [24]. The forebrain was dissected in half,
each sample cut into small pieces, and resuspended in ice
cold buffer (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM
PMSF, 1 mM aprotinin, 1mM leupeptin) for 10 min. Tissue
was homogenized by 30 strokes with a glass Dounce using a
loose pestle. Intact cell and nuclei were centrifuged for 10
min at 750 g. The supernatant was further centrifuged at
14,000 g for 20 min, and the resultant supernatant was
considered as cytosolic fraction and stored at #80 8C until
further analysis.
Material coming from different brains was never pooled.
Protein concentration was determined with a DC Protein
Assay Kit (Bio-Rad, Hercules, California, United States). Equal
amounts of protein (50 lg) were boiled for 5 min in SDS
loading buffer (50 mM Tris-Cl [pH 6.8], 2% SDS, 2% b-
Mercaptoethanol, 0.1% bromophenol blue, 10% glycerol);
resolved by 12%–15% SDS-PAGE gel, and transferred to
PVDF membranes (Immobilon P, Millipore, Bedford, Massa-
chusetts, United States) in a BioRad wet transfer unit. After
transfer was completed, membranes were stained with
Ponceau Red (Sigma) to verify loading, sample integrity, and
protein separation. Membranes were blocked with 5% nonfat
milk in TBS (10 mM Tris [pH 7.4]; 150 mM NaCl, 0.1% Tween
20) for 1 h, and then incubated overnight at 4 8C with primary
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antibody. The following antibodies were used: anti-active
caspase-3 antibody (1:1,000; Cell Signalling, Beverly, Massa-
chusetts, United States), anti-cytochrome-c antibody (1:1,000;
Pharmingen, San Diego, California, United States), anti-a-
tubulin antibody (1:40,000; Sigma). Washed membranes were
incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody (1:4000, Calbiochem, San
Diego, California, United States) 1 h at room temperature,
and immunoblotted proteins were detected by an enhanced
chemiluminiscent method (Pierce, Rockford, Illinois, United
States). For densitometric analysis, immunoreactive bands
were scanned and intensity quantitated using NIH Image
software (Scion, Frederick, Maryland, United States).
Ethanol Level Quantification
Blood and brain samples were collected at 4, 8, 12, and 24 h
after ethanol administration (see Table S1). Mice from eight
litters were sampled (n¼ 4 for each treatment group for each
time point). Blood was centrifuged at 3000 g for 20 min and
plasma stored at#20 8C until assayed. Brains were divided in
half and lysed in 600 ll of cold EB buffer (1% Triton X-100,
10 mM Tris-HCL [pH7.5], 150mM NaCl, 5 mM EDTA, 10%
Glycerol), centrifuged at 14,000 g for 20 min at 4 8C,
supernatant was collected and stored at#80 8C until assayed.
Aliquots were taken to measure protein concentration. 10 ll
of plasma and supernatant were used to determined ethanol
level using the Ethanol Assay kit (DCL, Charlottetown, Prince
Edward Island, Canada) in accordance with the manufac-
turer’s recommendations. All samples were run in duplicate
and averaged.
Morphological Analysis
Animals were sacrificed 24 h (Fluoro-Jade B) or 14 d (NeuN
[neuronal nuclear protein]) after ethanol treatment (see
Table S1). Five to six mice from a total of four different
litters were analyzed for each treatment group. After intra-
cardial perfusion with 4% of paraformaldehyde, brains were
removed and post-fixed overnight at 4 8C. Brains were cut
into 40-lm–thick transverse sections on a vibratome.
Fluoro-Jade–B Staining
Fluoro-Jade–B staining was performed as previously de-
scribed [25]. Briefly, sections were mounted on slides and then
air dried over night. The slides were immersed in a solution of
1% sodium hydroxide and 80% ethanol for 5min, then in 70%
alcohol for 2 min followed by 2 min in distilled water. Slides
were transferred in 0.06% potassium permanganate solution
for 10 min. After rinsed in water, slides were immersed in a
solution of 0.1% acetic acid and 0.0004% Fluoro-Jade B
(Calbiochem, San Diego, California, United States) for 20 min.
Slides were washed 33 in distillated water, allowed to dry at 55
8C for 10 min, and mounted with Krystalon (EMD Chemicals,
Gibbstown, New Jersey, United States).
NeuN Immunohistochemistry
For NeuN immunohistochemistry, floating sections were
incubated for 20 min in 3% H2O2. After rinsing in PBS,
sections were incubated 30 min in blocking solution (PBS,
10% goat serum, 0.3% Triton-X100). Sections were then
incubated with an anti-NeuN antibody (1:500; Chemicon,
Temecular, California, United States) overnight at 4 8C.
Sections were rinsed and incubated 1 h at room temperature
with biotinylated anti-mouse (1:200; Chemicon), followed by
the peroxidase-based Vectstain ABC system (Vector Labs,
Burlingame, California, United States) using diaminobenzi-
dine (Sigma) as the chromogen. Staining with NeuN is
markedly superior to that produced by the Nissl method:
neurons are stained with a greater intensity and with more
defined contours (personal observation and [26]). Counting of
neuronal populations with NeuN immunostaining is not only
comparable to that done with Nissl but may also reduce
errors when counting small neurons [26].
Cell Counting
Cells were counted one section out of every six (240 lm
apart from each other) throughout the brain by using a Nikon
Eclipse E600 with a Nikon 403objective. Two to four sections
per brain for the LDN (lateral dorsal nucleus) of thalamus,
and six to ten sections per brain for the CA1 and the
cingulate cortex were counted in five to six animals of each
group. Cells were counted in both hemispheres. Contours of
Cingulate CX (Bregma from 1.34 to #0.82), CA1 (dorsal part
Bregma from#1.22 to#1.84; ventral part Bregma from#3.52
to #.88) and LDN (Bregma from #1.06 to #1.46) [27] were
traced using a personal computer, and the area was calculated
with Stereo Investigator software (MBF Bioscience, Williston,
Vermont, United States). The section thickness was measured
at different random locations, and the range was: 8–12 lm for
Fluoro-Jade B and 18–22 lm for NeuN stain. The relative area
densities (counts/mm2) of Fluoro-Jade B–positive cell profiles
were estimated using the fractionator probe and systematic
random sampling (MBF Bioscience), and counting was done
between 2–5 d after staining the sections for Fluoro-Jade B.
There was no significant fading of fluorescence when
randomly selected sections were recounted blindly 10 d later,
agreeing with previously published data [25]. Pilot studies
revealed no consistent differences in profile size between
control and treated animals. The density of NeuNþ cells
(counts/mm3) was estimated with the optical dissector
method, which has been described previously [28–30]. The
results were normalized and expressed as percentage of
control. Briefly, the number of neurons (Q) was counted in a
dissector volume (Vdis) defined by the product of a counting
frame and the distance between two dissectors planes (h). The
density of cells (Nv) was determined by dividing the total
number of counting cells (Q) by the total volume in which
cells were counted (Vdis). Twenty-five to 30 different fields
were randomly selected for each region in each section
analyzed and a total of 200–400 cells/region/brain were
counted with a CE of 0.07–0.05. The dimension of the
counting frame was 503 50 lm with a dissector depth (h) of
12 lm for the cingulate cortex and the LDN of thalamus,
while for the CA1 region it was 20 3 20 lm with a dissector
depth of 8 lm. A 2-lm guard space from the top was used.
Counting was conducted in a blinded manner.
Behavioral Tests
P7 mice received subcutaneous injection of saline or
ethanol, and nicotinamide was administrated 2 h later. The
different treatments were distributed across sexes and litters
as evenly as possible. Animals remained with the lactating
dam until P21, at which time they were separated by sex and
housed under a 12:12 h light/dark cycle in a temperature- and
humidity-controlled animal facility. Behavioral tests were
started on P60 and the total time necessary to run all tests was
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5–6 wk. Thirty-one to 34 animals (from a total of 16 different
litters) were sampled for each treatment group (see Table S1).
All the experiments were conducted in a blind manner.
Animals were separated by treatment and four to five animals
were housed per cage. A person who did not know how the
mice have been treated coded each cage. At the end of the
entire behavioral test, the codes were opened. Mice were
tested in open field, plus maze, and fear conditioning tests,
tests widely used to study behavioral changes in animal
expose to ethanol in the perinatal period [31–34].
Open Field
The open field test was performed as described previously
[33,35]. Mice were placed in a 503 50 cm square chamber for
5 min. The floor was divided into nine squares. The test was
conducted in the dark. Each mouse was place in the center of
the box. Each session was videotaped. Horizontal (lines
crossed) and vertical (rearing) activities were recorded.
Elevated Plus Maze
Elevated plus maze was performed as described previously
[33,36]. The apparatus consisted of two open arms (30 3 5
cm), two closed arms (303 5 cm with 15 cm high black wall),
and a connecting central platform (535 cm). Each mouse was
placed in the center facing one open arm and then allowed to
explore the maze for 5 min. The test was conducted in the
dark light. Animals were videotaped and scored for total
entries into all arms, percent of total entries into the open
arm, and percent of total time spent in the open arms.
Fear Conditioning
The fear conditioning test was performed as described
previously [31,37]. On day 1 of training, mice were placed
individually in the conditioning chamber (chamber A)
(Coulbourn Instruments, Allentown, Pennsylvania, United
States). After 2 min of habituation, three tone-shock pairs
were given at 1-min intervals. Each tone-shock pair consisted
of a 20-s acoustic white noise tone (CS) (70db, 2.9KHz),
followed by a 1-s foot shock (US). One minute after the third
shock, mice were returned to their home cage. On day 2, mice
were placed in the same environment (contextual condition-
ing), and the total freezing (cessation of all movement other
than respiration) time was measured for 5 min. On day 3,
mice were placed in a different chamber (chamber B) and
after 120 s three separate CS of 20 s were delivered at 1 min
intervals (cued conditioning). Freezing was scored and
expressed as the percentage of time spent freezing. To
exclude the possibility that differences in the time freezing
were due to an altered activity, the basal level of freezing in
the animals was scored for 2 min the first day before the
training (pre-testing) and the third day before the presenta-
tion of the tone (pre-tone). Some of the animals were not
scored in the pre-training and in the pre-tone analysis
because the videotape was not available.
Data Analysis
Statistical analyses were performed with STAT VIEW
software (SAS Institute, Cary, North Carolina, United States).
Data are presented as mean 6 standard deviation (SD).
Statistical analyses were made using analysis of variance
(ANOVA), and Bonferroni’s procedure was used for multiple
comparison analysis.
Results
Nicotinamide Inhibits Ethanol-Induced Apoptotic Pathway
P7 mice were injected subcutaneously with a 20% solution
of ethanol in normal saline delivering 5 g/kg, and sacrificed at
different time points. This dose maintained a blood ethanol
concentration above 200 mg/dl for several hours, which is the
minimum level needed for triggering neurodegeneration
consistently [12,14]. This blood ethanol level is in the range
that a human fetus might be exposed to after maternal
ingestion of a moderate to heavy dose of ethanol [38]. A clear
activation of caspase-3 was observed 4 h after ethanol
administration; it peaked at 12 h and was still evident 24 h
after ethanol treatment (Figure S1A).
In order to determine if nicotinamide can inhibit ethanol-
induced caspase-3 activation, a series of different experi-
ments was performed (Figure 1). In a first set of experiments,
increasing doses of nicotinamide were administered subcuta-
neously 2 h after ethanol exposure. 12 h after treatment,
animals injected with ethanol alone showed a 15-fold to 20-
fold increase of cleaved caspase-3 compared with a saline
control (Figure 1A and 1C; Table S2). Administration of
nicotinamide reduced caspase-3 activation, and maximum
inhibition was seen with a 1 mg/g dose (Figure 1A and 1C;
Table S2). To rule out the possibility that nicotinamide might
only delay caspase-3 activation, we evaluated the effects of
nicotinamide on caspase-3 activation 24 h after ethanol
administration. Cleaved caspase-3 was increased 3-fold–4-
fold in ethanol-treated mice compared with controls (Figure
1B and 1D; Table S3). However, one single injection of
nicotinamide 2 h after ethanol administration was sufficient
to reduce ethanol-induced caspase-3 activation by approx-
imately 50% after 24 h (Figure 1B and 1D; Table S3).
In a second set of experiments, animals received nicotina-
mide (1 mg/g) at 0, 2, 4, or 8 h after ethanol administration.
Activation of caspase-3 was assessed 12 h after ethanol
exposure. We found that nicotinamide treatment prevented
ethanol-induced activation of caspase-3 at all time points
tested, and the strongest effect was observed when nicotina-
mide was administered between 0 h and 2 h after ethanol
exposure (Figure 1E and 1G; Table S4).
To verify that nicotinamide was also able to prevent the
ethanol-induced activation of caspase-3 at a lower ethanol
concentration, mice were exposed to 2.5, 4, or 5g/kg of
ethanol, and nicotinamide was injected 2 h later. A dose of 2.5
g/kg was not enough to consistently detect caspase-3
activation 12 h after ethanol treatment in the whole forebrain
(Figure 1F and 1H). Nicotinamide administration prevented
ethanol-induced activation of caspase-3 at 4 or 5g/kg of
ethanol exposure (Figure 1F and 1H; Table S5).
Finally, to test the specificity of actions of nicotinamide, we
administrated 1-methyl-nicotinamide, an analogue of nicoti-
namide, 2 h after ethanol exposure. This analogue is not
converted into NADþ, and its administration did not prevent
ethanol-induced caspase-3 activation (Figure S2B and S2C;
Table S6).
Based on these findings, ethanol was administered at 5 g/kg
and nicotinamide at 1 mg/g, 2 h after ethanol treatment in the
rest of the experiments.
Release of cytochrome-c into the cytoplasm induces the
formation of apoptosome, which in turn activates caspase-3
[14, 23]. Recently, it has been shown that ethanol-induced
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neuronal death is Bax-dependent and involves the release of
cytochrome-c from the mitochondria [39]. Since nicotina-
mide can block the cytochrome-c release in vitro, we tested
whether inhibition of cytochrome-c release might be the
target of nicotinamide in vivo (Figure 2). Figure 2A and 2C
shows that in ethanol-treated pups there is a 20-fold increase
of cytochrome-c release after 12 h compared with controls,
and that administration of nicotinamide significantly re-
duced this release (Figure 2A and 2C; Table S7).
Nicotinamide Does Not Alter the Metabolism of Ethanol
Metabolism of ethanol through alcohol dehydrogenase
requires NADþ with production of acetaldehyde. Further
oxidation of acetaldehyde is mediated predominantly by the
mitochondrial aldehyde dehydrogenase, which also needs
NADþ. Therefore, the rate-limiting factor in the metabolism
of ethanol is the amount of NADþ. It has been shown that
administration of nicotinamide increases the level of NADþ
[17]. To test if nicotinamide could modify the metabolism of
Figure 1. Nicotinamide Inhibits Ethanol-Induced Caspase-3 Activation
(A–D) P7 mice were injected with ethanol and received nicotinamide 2 h later.
(A and B) Level of cleaved caspase-3 was analyzed by Western blot at 12 h (A) and 24 h (B) after ethanol administration with different doses of
nicotinamide.
(C and D) Densitometric quantification of cleaved caspase-3 at 12 h (ANOVA F5,27¼ 10.989; p , 0.0001; n¼ 5–6 each treatment group) (C) and 24 h
(ANOVA F3,18 ¼ 8.851; p¼ 0.0008; n¼ 6 each treatment group) (D).
(E and G) Nicotinamide was administered to P7 mice at different time points after ethanol exposure. Western blot analysis of caspase-3 activation 12 h
after ethanol injection (E) and densitometric quantification (ANOVA F5,33 ¼ 15.061; p , 0.0001; n ¼ 6–7 each treatment group) (G).
(F and H) Different doses of ethanol were administered to P7 mice and nicotinamide was injected 2 h later. Western blot analysis of caspase-3 activation
12 h after ethanol injection (F) and densitometric quantification (ANOVA F6,28¼ 18.183; p , 0.0001; n¼ 5 each treatment group) (H). Values are shown
as mean 6 SD. Bonferroni correction for multiple comparisons revealed a significant difference between the ethanol treatment group and all other
groups. $p , 0.0001.
DOI: 10.1371/journal.pmed.0030101.g001
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ethanol, we measured alcohol level in the blood and in the
brain at several time points after ethanol administration, with
and without nicotinamide. Figure 2B and 2D shows that 1mg/
g of nicotinamide did not change the pharmacokinetics of
ethanol (as alcohol levels neither in the blood nor in the brain
were affected) (Figure 2B and 2D).
Nicotinamide Inhibits Ethanol-Induced Neuronal Death
Following activation, caspase-3 is responsible for the
cleavage of a broad spectrum of cellular targets, ultimately
leading to cell death. In addition, other caspase-3 independ-
ent mechanisms may also be involved in apoptotic cell death.
To determine whether inhibition of caspase-3 activation by
nicotinamide is sufficient to prevent ethanol-induced cell
death, brains were histologically analyzed for evidence of
neurodegeneration. 24 h after ethanol treatment, Fluoro-
Jade–B staining, predominantly a marker of neuronal injury
[25], revealed neurodegeneration throughout the forebrain of
ethanol-treated mice. In contrast, mice that received nicoti-
namide after ethanol administration showed a dramatic
reduction in Fluoro-Jade–B labeling (Figure 3A). Quantifica-
tion of Fluoro-Jade–B positive cells in regions particularly
sensitive to ethanol at this developmental stage (anterior
cingulate cortex, CA1 of the hippocampus, and LDN of
thalamus), confirmed that administration of nicotinamide
reduced the number of neurons injured by ethanol exposure
(Figure 3B). Furthermore, using NeuN, a marker of mature
neurons [26], we established that there was a significant
decrease in the number of mature neurons in the anterior
cingulate cortex (488,792 6 11,828 versus 450,392 6 5,548; p
¼ 0.01) and in the LDN of the thalamus (255,588 6 11,583
versus 206,022 6 13,017; p ¼ 0.004) 14 d after ethanol
exposure. In the hippocampus, while there was only a trend
in the dorsal CA1 region (641,056 6 38,388 versus 570,796 6
26,311; p ¼ 0.08), a significant statistical difference was
present in the ventral region (707,552 6 47,241 versus
556,756 6 21,322; p ¼ 0.02). Nicotinamide treatment
prevented the ethanol-induced decrease of the number of
neurons in all of these regions (Figure 3C).
Nicotinamide Prevents Ethanol-Induced Behavioral
Impairment in Adult Mice
Rodents exposed to ethanol during early development
show several behavioral and cognitive impairments as adults,
and these impairments appear to correlate with ethanol-
induced neuronal loss [33,40–42]. We have shown here that
nicotinamide inhibits the decrease in the number of neurons
following ethanol exposure during early postnatal develop-
ment. To examine if this effect on neuronal death could
prevent behavioral deficits, we conducted a series of
behavioral tests on adult mice that had been exposed to
ethanol during early development. Animals were exposed to
Figure 2. Nicotinamide Blocks Release of Cytochrome-C from Mitochondria
(A) Western blot analysis of cytochrome-c release in the cytosolic fraction 12 h after ethanol administration.
(C) Densitometric quantification of cytochrome-c release (ANOVA F3,20¼ 43.546 p , 0.0001; n¼ 6 each treatment group). Values are shown as mean 6
SD. Bonferroni correction for multiple comparison revealed a significant difference between ethanol treatment group and all other groups. $p, 0.0001.
(B and D) Nicotinamide (1mg/g) does not alter ethanol absorption or excretion. Ethanol levels in blood (B) and brain (D) were measured at different time
points after 5g/kg of ethanol treatment in P7 mice. Nicotinamide was administered 2 h after ethanol exposure. No significant differences were seen
between the different treatments (n¼ 4 each treatment group).
DOI: 10.1371/journal.pmed.0030101.g002
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either saline, ethanol, ethanol/nicotinamide, or saline/nicoti-
namide at P7. Mice were tested starting at 2 mo of age, and all
behavioral tests were conducted blind to the treatment. First,
we assessed spontaneous locomotor activity by placing the
mice in the open field box for 5 min. Ethanol-treated mice
showed increases in the number of lines crossed (horizontal
activity) but not in the number of rears (vertical activity)
(Table 1 and unpublished data). Administration of 1 mg/g
nicotinamide alone did not influence the spontaneous
activity of the mice, compared with saline-treated mice
Figure 3. Nicotinamide Inhibits Ethanol-Induced Neurodegeneration
(A) Fluoro-Jade B staining 24 h after ethanol treatments.
(B) Quantification of Fluoro-Jade–B positive cells in the cingulate cortex (ANOVA F2,13¼ 25.541; p , 0.0001; n¼ 5–6 each treatment group), in the total
CA1 region of hippocampus (ANOVA F2,13¼ 9.988; p¼ 0.0024; n¼ 5–6 each treatment group), and in the LDN of thalamus (ANOVA F2,13¼ 20.785; p ,
0.0001; n¼ 5–6 each treatment group).
(C) Total number of NeuN positive cells were counted 2 wk after ethanol administration in the cingulate cortex (ANOVA F2,12¼ 9.894; p¼ 0.0029; n¼ 5
each treatment group), in the CA1 region of hippocampus (ANOVA F2,12¼ 7.289; p¼ 0.0085; n¼ 5 each treatment group) and in the LDN of thalamus
(ANOVA F2,12¼5.551; p¼ 0.0196; n¼5 each treatment group). Values are shown as mean6 SD. Bonferroni correction for multiple comparison revealed
a significant difference between ethanol treatment group and all other groups.
S, saline; E, ethanol; EtohþNic, ethanolþ nicotinamide. Scale bars 200lm.
DOI: 10.1371/journal.pmed.0030101.g003
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(Table 1). However when nicotinamide was administrated
after ethanol in P7 mice, it completely prevented the increase
of activity exhibited in adult ethanol-treated mice (Table 1).
The mice were then tested in the elevated plus maze. This
task relies on the conflict between a mouse’s natural aversion
to open space and its exploratory behavior. Entries into the
open arms are indicative of reduced anxiety or fear, while the
total entries into all the arms correlate with activity level [35].
Ethanol-treated mice showed an increase in the total number
of entries into both open and closed arms, indicating
increased activity (Table 1). Furthermore, ethanol-treated
mice made more entries into the open arms and also stayed
there for longer periods of time (Table 1). In contrast,
ethanol-treated mice that received nicotinamide did not
show any differences when compared with saline-treated
mice (Table 1).
Finally, to test hippocampal learning and memory we used
a fear-conditioning paradigm. In this test, mice learn to
associate a context (experimental chamber) or cue (tone) with
a foot shock. Contextual fear conditioning is hippocampus-
dependent, while cued fear conditioning is hippocampus-
independent. Prior to presentation of the first shock/tone
pairing, all the mice showed a low level of freezing, and
ANOVA analysis did not show any difference between the
different groups (F3,65 ¼ 2.271; p ¼ 0.0885; n ¼ 16–18 each
treatment group) (Table 2). 24 h after training, ethanol-
treated mice showed significant impairment in contextual
fear conditioning, displaying a significantly decreased level of
freezing. Nicotinamide administration completely prevented
the performance impairment induced by ethanol (Table 2).
Furthermore, 48 h after training, the same mice were tested
with the conditioned stimulus (tone) in a novel chamber. All
groups displayed similar and statistically indistinguishable
freezing responses in both the new context before (pre-tone:
ANOVA F3,122 ¼ 1.074; p ¼ 0.3626; n ¼ 31–33 each treatment
group) and during the presentation of tone cue (tone:
ANOVA F3,128 ¼ 1.312; p ¼ 0.2733; n ¼ 31–34 each treatment
group) (Table 2). These results suggest that exposure to
ethanol, in the postnatal period, affects hippocampal-
dependent memory in adult mice.
Discussion
In this study, we have demonstrated that the administra-
tion of nicotinamide after ethanol treatment in early
postnatal development prevents alcohol-induced hyperactiv-
ity and memory impairment in adult mice. The memory
impairment in contextual fear conditioning and behavioral
hyperactivity both correlated with an increase in neuronal
death in cingulate cortex and hippocampus. Administration
of nicotinamide protected against this ethanol-induced
apoptosis, suggesting a link between neuronal loss during
brain development and behavioral disturbances observed in
the adult mice. Interestingly, we established that adminis-
tration of ethanol in postnatal mice induced extensive
neuronal death predominantly in the ventral region of the
hippocampus. This is consistent with recently published
findings that damage to the ventral part of hippocampus
significantly impairs performance in contextual fear con-
ditioning [43]. Our findings of an increase in the number of
entries into the open arm and in the time of permanence in
the open arm in ethanol-treated mice are consistent with
data previously published [33,44]. However, to better under-
stand whether this behavioral phenotype is due to an
anxiolytic effect or simply to an increase of activity,
additional studies are needed.
Table 1. Nicotinamide Reverts Ethanol-Induced Hyperactivity in Adult Mice
Test Treatment n Mean SD 95% CI Low 95% CI High p-Valuea Saline p-Valuea EtOH
Open Field
Total lines crossed
Saline 33 128.097 32.312 117.073 139.121 0 0.0012
EtOH 34 158.471 42.157 144.301 172.641 0.0012 0
EtOH þ Nic 33 125.242 30.927 114.690 135.794 0.7569 0.0003
Saline þ Nic 31 132.030 40.039 117.935 146.125 0.6698 0.0039
Plus Maze
Total entries
Saline 33 16.469 4.813 14.827 18.111 0 0.0030
EtOH 34 20.118 5.698 18.203 22.033 0.0030 0
EtOH þ Nic 33 16.515 5.026 14.800 18.230 0.9695 0.0031
Saline þ Nic 31 15.030 3.795 13.694 16.366 0.2378 ,0.0001
% Entries in open arms
Saline 33 8.841 8.956 5.785 11.897 0 0.001
EtOH 34 18.950 14.366 14.121 23.779 0.001 0
EtOH þ Nic 33 10.388 11.881 6.334 14.442 0.6087 0.0046
Saline þ Nic 31 9.299 12.598 4.864 13.734 0.8794 0.0015
% Time in open arms
Saline 33 3.866 5.549 1.973 5.759 0 0.0007
EtOH 34 10.176 9.765 6.894 13.458 0.0007 0
EtOH þ Nic 33 4.919 6.645 2.652 7.186 0.564 0.0040
Saline þ Nic 31 4.374 6.544 2.070 6.678 0.7809 0.0015
ap-Value from ANOVA followed by Bonferroni correction. Comparisons are considered significant with a p-value less than 0.083.
Boldfaced numbers indicate p-values that are significant.
DOI: 10.1371/journal.pmed.0030101.t001
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Neuroprotection by nicotinamide in ethanol toxicity
appears to function at the mitochondrial level. In the
present study, we show that nicotinamide in vivo prevents
ethanol-induced cytochrome-c release and the following
caspase-3 activation. Our data are consistent with previous
studies showing that nicotinamide inhibits oxygen-glucose
deprivation-induced neuronal death in vitro, by preventing
release of cytochrome-c [23]. Although the determination of
the precise mechanisms underlying the effects of nicotina-
mide require furthers analysis, it is possible that nicotina-
mide may function in stabilizing the cellular energy
metabolism [16]. During an oxidative stress, depletion of
NADþ is considered a critical factor in precipitating cell
death due to compromised energy supply [45]. Administra-
tion of nicotinamide increases the amount of NADþ in the
brain, preventing its depletion and consequent energetic
decline [17,46]. This is consistent with a recent study in which
increasing NADþ biosynthesis prevented axonal degenera-
tion [47].
Although there are other studies showing a possible
protective effect of antioxidants in preventing ethanol-
induced apoptotic neuronal death, to our knowledge this is
the first treatment that has been shown to work at the
molecular, cellular, and behavioral levels. It has been shown
that treatment with the synthetic antioxidant ebselen
decreases ethanol-induced apoptotic cell death of young
neurons in the adult dentate gyrus [48]. Administration of an
active fragment of the glial-derived activity-dependent
neuroprotective protein, which has potent anti-oxidative
properties, prevents ethanol-induced growth retardation in
mouse whole-embryo culture and neurotoxicity in vitro [49].
Other studies have demonstrated that vitamin E and b-
carotene protect against ethanol-induced neuronal death in
vitro [50,51]. However, the protective effects of vitamin E in
vivo are controversial. While Heaton et al. [52] have shown
that vitamin E protects against ethanol-induced loss of
Purkinje cells of the cerebellum, Tran et al. [53] have found
that vitamin E does not prevent ethanol-induced caspase-3
activation, cerebellar damage, or behavioral impairment.
Furthermore, it has been shown that while a pretreatment
with a large dose of vitamin E prevents ethanol-induced cell
loss and oxidative stress in the neonatal rat hippocampus, this
treatment did not prevent behavioral impairment in ethanol-
exposed mice [54].
Although nicotinamide was previously used in another
model of FAS [55], the present study has demonstrated for
the first time that nicotinamide exerts a protective effect
against ethanol-induced apoptotic cell death and adult
neurobehavioral disturbances. We tested nicotinamide be-
tween 0 h and 8 h after administration of ethanol, and while
we saw the highest level of protection between 0 h and 2 h,
nicotinamide treatment retained some effect even after a
delay of 8 h (Figure 1E and 1G; Table S4). We used a dose of
ethanol that achieved extremely high blood levels that were
maintained for more than 12 h, and yet we were able to
reverse the neurobiological effects of ethanol. An important
aspect of our study is that nicotinamide has been used for
several years in some clinical trials to treat type-I diabetes
and bullous pemphigoid (a chronic, autoimmune, blistering
disease), orally and in large daily doses for up to five years
with little or no side effects [56–59]. Furthermore, there is
no evidence that nicotinamide is teratogenic by itself [60]. In
conclusion, although additional studies are necessary, we
suggest, based on the data presented here, that nicotina-
mide, a readily available and safe agent, could eventually be
used in the treatment and prevention of the devastating
sequellae of FAS.
Table 2. Nicotinamide Prevents Ethanol-Induced Impairment Performance in the Contextual Fear-Conditioning Test
Test Treatment n Meana SD 95% CI Low 95% CI High p-Valueb Saline p-Valueb EtOH
Pre-training
Saline 18 3.002 3.252 1.500 4.754 ns Ns
EtOH 18 0.763 2.447 #0.367 3.577 ns Ns
EtOH þ Nic 16 1.926 3.427 0.247 5.106 ns Ns
Saline þ Nic 17 1.201 1.413 0.529 2.085 ns Ns
Context
Saline 33 33.656 14.561 28.688 19.529 0 0.0002
EtOH 34 21.540 11.320 17.735 15.125 0.0002 0
EtOH þ Nic 33 29.933 11.813 25.903 15.843 0.2399 0.0078
Saline þ Nic 31 33.752 13.003 29.175 17.580 0.9759 0.0001
Pre-tone
Saline 33 16.819 10.698 13.169 14.348 ns ns
EtOH 31 14.547 8.678 11.492 11.733 ns ns
EtOH þ Nic 31 13.798 8.164 10.924 11.038 ns ns
Saline þ Nic 31 17.104 7.617 14.423 10.298 ns ns
Tone
Saline 33 53.190 14.165 48.357 18.998 ns ns
EtOH 34 51.459 18.381 45.281 24.559 ns ns
EtOH þ Nic 33 55.864 17.513 49.889 23.488 ns ns
Saline þ Nic 31 60.496 16.901 54.547 22.850 ns ns
a% of time spent freezing.
bp-Value from ANOVA followed by Bonferroni correction. Comparisons are considered significant with a p-value less than 0.083.
Boldfaced numbers indicate p-values that are significant.
ns, not significant.
DOI: 10.1371/journal.pmed.0030101.t002
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Supporting Information
Alternative Language Abstract S1. Italian Translation of the Abstract
Found at DOI: 10.1371/journal.pmed.0030101.sd001 (29 KB PDF).
Alternative Language Abstract S2. Spanish Translation of the
Abstract
Found at DOI: 10.1371/journal.pmed.0030101.sd002 (35 KB PDF).
Figure S1. Ethanol Induces Activation of Caspase-3
(A) Ethanol was injected into P7 mice, and activation of caspase-3 was
detected at a different time point by Western blot. (B and C) 1-
methylnicotinamide does not prevent ethanol-induced activation of
caspase-3. P7 mice were injected with ethanol and nicotinamide or 1-
methylnicotinamide, an analogue of nicotinamide, administered 2 h
after ethanol exposure. At the dose of 1 mg/g, 1-methyl-nicotinamide
was toxic. Western blot analysis of activated caspase-3 12 h after
ethanol exposure (B) and correspondent densitometric quantification
(ANOVA F4,18¼ 10.705 p¼ 0.0014; n¼ 4–5 each treatment group) (C).
Values are shown as mean 6 SD. Multiple comparison by
Bonferroni’s procedure revealed a significant difference between
the ethanol treatment group and all other groups. No statistical
differences were present between ethanol and ethanol plus 1-methyl-
nicotinamide.
Found at DOI: 10.1371/journal.pmed.0030101.sg001 (1.1 MB PDF).
Table S1. Experimental Groups
Found at DOI: 10.1371/journal.pmed.0030101.st001 (53 KB DOC).
Table S2. Nicotinamide InhibitsEthanol-InducedCaspase-3Activation
Western blot densitometric analysis of caspase-3 activation 12 h after
ethanol treatment and different doses of nicotinamide administration.
Found at DOI: 10.1371/journal.pmed.0030101.st002 (31 KB DOC).
Table S3. Nicotinamide InhibitsEthanol-InducedCaspase-3Activation
Western blot densitometric analysis of caspase-3 activation 24 h after
ethanol treatment.
Found at DOI: 10.1371/journal.pmed.0030101.st003 (28 KB DOC).
Table S4. Nicotinamide InhibitsEthanol-InducedCaspase-3Activation
Western blot densitometric analysis of caspase-3 activation 12 h after
ethanol treatment and different time points of nicotinamide
administration.
Found at DOI: 10.1371/journal.pmed.0030101.st004 (31 KB DOC).
Table S5. Nicotinamide InhibitsEthanol-InducedCaspase-3Activation
Western blot densitometric analysis of caspase-3 activation 12 h after
different doses of ethanol administration.
Found at DOI: 10.1371/journal.pmed.0030101.st005 (31 KB DOC).
Table S6. Nicotinamide InhibitsEthanol-InducedCaspase-3Activation
Western blot densitometric analysis of caspase-3 activation 12 h after
ethanol treatment using nicotinamide or an analogue of nicotinamide.
Found at DOI: 10.1371/journal.pmed.0030101.st006 (29 KB DOC).
Table S7. Nicotinamide Blocks Release of Citochrome-c from
Mitochondria
Western blot densitometric analysis of cytochrome-c release from
mitochondria 12 h after ethanol administration.
Found at DOI: 10.1371/journal.pmed.0030101.st007 (28 KB DOC).
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Patient Summary
Background. When a woman drinks alcohol while she is pregnant, the
alcohol goes to the baby through her bloodstream and can harm the
baby. Some babies whose mothers had been drinking alcohol during
pregnancy are born with fetal alcohol syndrome (FAS), a serious
condition that can affect a child throughout life. Children with FAS
have problems with development, learning, behavior, and social skills. In
many Western countries, FAS is a common cause of mental retardation.
Nicotinamide is a drug that has been used orally in patients with type-I
diabetes and bullous pemphigoid (a chronic, autoimmune, blistering
disease) and is generally well-tolerated.
Why Was This Study Done? Nicotinamide has also been found to have
neuroprotective properties (that means it can protect nerve cells).
Because some of the problems associated with FAS are thought to be
caused by the alcohol killing cells in the baby’s brain, the researchers
wanted to test whether nicotinamide could prevent some of the
consequences of alcohol exposure. Before one can start testing such
potential treatments in humans, it is necessary to do extensive studies in
animal models (and only a small proportion of ideas that look promising
in animal studies will eventually turn into useful treatments for human
patients).
What Did the Researchers Do and Find? They injected mouse pups
shortly after birth with alcohol. Mouse brain development happens a bit
later than in humans, and the time shortly after birth in mice
corresponds to brain development in human babies during the third
trimester of pregnancy. They found that this single exposure to alcohol
(which is comparable with one-time excessive drinking in a pregnant
mother) caused the death of brain cells in the mouse pups as well as a
range of behavioral abnormalities after the pups had grown into adult
mice. When they followed the injection of alcohol with a second
injection of nicotinamide two hours later, the number of brain cells that
died was no greater than during normal brain development, and the
mice did not show behavioral abnormalities as adults.
What Do These Findings Mean? This means that it might be possible,
some years from now, to prevent some of the alcohol damage to the
baby if the mother gets nicotinamide treatment soon after she was
drinking alcohol. However, these are early-stage experiments done in a
mouse model of FAS, and much more work is needed before it will
become clear whether this or a similar treatment would work at all in
humans. Moreover, FAS causes severe birth defects that are entirely
preventable if a pregnant woman doesn’t drink. Changing the behavior
of pregnant women (and those who might become pregnant) therefore
must be and will remain the focus of medical care.
Where Can I Get More Information Online? The following Web sites
have information on fetal alcohol syndrome.
National Organization of Fetal Alcohol Syndrome:
http://www.nofas.org/about
The US Centers for Disease Control and Prevention (a list of relevant
publications):
http://www.cdc.gov/ncbddd/fas/faspub.htm
Australian Health Insite:
http://www.healthinsite.gov.au/topics/Foetal_Alcohol_Syndrome
Health on the Net Foundation:
http://www.hon.ch/Dossier/MotherChild/neonatal_problems/
fetal_alcohol.html
US National Institute on Alcohol Abuse and Alcoholism:
http://www.niaaa.nih.gov/AboutNIAAA/Interagency/AboutFAS.htm
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